| Medical and Health Sciences | Lifetime | 575 | NL 16 | 99.97 |
| Medical and Health Sciences | 2021-2025 | 10 | NL 1 | 100.00 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 30 | NL 1 | 99.88 |
| Nephrology | Lifetime | 28 | NL 1 | 99.78 |
| Cardiology and Cardiovascular Medicine | Lifetime | 628 | NL 23 | 98.94 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 1 | NL 1 | 99.98 |
| Nephrology | 2021-2025 | 1 | NL 1 | 99.95 |
| Surgery | 2021-2025 | 147 | NL 3 | 99.14 |
| Medical Physiology | 2021-2025 | 141 | NL 4 | 98.34 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 256 | NL 13 | 97.92 |
| Molecular Biology | 2021-2025 | 606 | NL 7 | 96.72 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 592 | NL 17 | 93.16 |
| Statistics and Probability | 2021-2025 | 195 | NL 8 | 87.46 |
| Chronic Kidney Disease and Diabetes | Lifetime | 16 | NL 2 | 99.82 |
| Diabetes Treatment and Management | Lifetime | 26 | NL 1 | 99.84 |
| Pancreatic function and diabetes | Lifetime | 56 | NL 2 | 99.73 |
| Blood Pressure and Hypertension Studies | Lifetime | 74 | NL 3 | 99.66 |
| Renal Diseases and Glomerulopathies | Lifetime | 46 | NL 3 | 99.56 |
| Diabetes Management and Research | Lifetime | 98 | NL 1 | 99.52 |
| Dialysis and Renal Disease Management | Lifetime | 84 | NL 5 | 99.49 |
| Hormonal Regulation and Hypertension | Lifetime | 138 | NL 5 | 99.21 |
| Metabolism, Diabetes, and Cancer | Lifetime | 165 | NL 3 | 99.22 |
| Potassium and Related Disorders | Lifetime | 30 | NL 2 | 99.29 |
| Pharmacology and Obesity Treatment | Lifetime | 78 | NL 2 | 98.88 |
| Heart Failure Treatment and Management | Lifetime | 697 | NL 23 | 97.60 |
| Erythropoietin and Anemia Treatment | Lifetime | 200 | NL 8 | 96.70 |
| Renal and Vascular Pathologies | Lifetime | 876 | NL 37 | 95.52 |
| Sodium Intake and Health | Lifetime | 320 | NL 8 | 95.23 |
| Electrolyte and hormonal disorders | Lifetime | 798 | NL 21 | 94.37 |
| Renin-Angiotensin System Studies | Lifetime | 723 | NL 20 | 94.16 |
| Statistical Methods in Clinical Trials | Lifetime | 682 | NL 31 | 93.40 |
| Pancreatic function and diabetes | 2021-2025 | 1 | NL 1 | 99.95 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 1 | NL 1 | 99.96 |
| Diabetes Treatment and Management | 2021-2025 | 3 | NL 1 | 99.97 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 4 | NL 1 | 99.81 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 4 | NL 1 | 99.80 |
| Diabetes Management and Research | 2021-2025 | 10 | NL 1 | 99.75 |
| Hormonal Regulation and Hypertension | 2021-2025 | 5 | NL 1 | 99.77 |
| Nitric Oxide and Endothelin Effects | 2021-2025 | 3 | NL 1 | 97.52 |
| Dialysis and Renal Disease Management | 2021-2025 | 20 | NL 2 | 99.24 |
| Diet and metabolism studies | 2021-2025 | 55 | NL 2 | 99.10 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 31 | NL 1 | 99.33 |
| Potassium and Related Disorders | 2021-2025 | 14 | NL 1 | 98.90 |
| Pharmacology and Obesity Treatment | 2021-2025 | 19 | NL 1 | 97.89 |
| Apelin-related biomedical research | 2021-2025 | 9 | NL 1 | 92.84 |
| Heart Failure Treatment and Management | 2021-2025 | 247 | NL 11 | 97.03 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 47 | NL 2 | 94.29 |
| Ion Transport and Channel Regulation | 2021-2025 | 41 | NL 4 | 92.68 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 839 | NL 33 | 94.77 |
| Statistical Methods in Clinical Trials | 2021-2025 | 159 | NL 10 | 89.99 |
| Pancreatitis Pathology and Treatment | 2021-2025 | 693 | NL 36 | 89.41 |
| Electrolyte and hormonal disorders | 2021-2025 | 152 | NL 9 | 87.36 |
| Renal Transplantation Outcomes and Treatments | 2021-2025 | 874 | NL 45 | 87.68 |
| Biomedical Research and Pathophysiology | 2021-2025 | 123 | NL 13 | 78.11 |
| Renin-Angiotensin System Studies | 2021-2025 | 145 | NL 6 | 74.77 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 540 | NL 11 | 70.82 |
| Neurological and metabolic disorders | 2021-2025 | 222 | NL 12 | 70.50 |
| Advanced Causal Inference Techniques | 2021-2025 | 816 | NL 33 | 57.37 |
